Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

Similar articles for PubMed (Select 21083643)

1.

Early prostate cancer--which treatment do men prefer and why?

Anandadas CN, Clarke NW, Davidson SE, O'Reilly PH, Logue JP, Gilmore L, Swindell R, Brough RJ, Wemyss-Holden GD, Lau MW, Javle PM, Ramani VA, Wylie JP, Collins GN, Brown S, Cowan RA; North West Uro-oncology Group.

BJU Int. 2011 Jun;107(11):1762-8. doi: 10.1111/j.1464-410X.2010.09833.x. Epub 2010 Nov 17.

PMID:
21083643
2.

Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.

van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF.

BJU Int. 2013 Apr;111(4):564-73. doi: 10.1111/j.1464-410X.2012.11402.x. Epub 2012 Aug 10.

PMID:
22882966
3.

Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.

Baade PD, Youlden DR, Gardiner RA, Ferguson M, Aitken JF, Yaxley J, Chambers SK.

BJU Int. 2012 Dec;110(11 Pt B):E712-9. doi: 10.1111/j.1464-410X.2012.011533.x. Epub 2012 Sep 27.

PMID:
23017157
4.

Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey.

Hall JD, Boyd JC, Lippert MC, Theodorescu D.

Urology. 2003 Feb;61(2):402-7.

PMID:
12597956
5.

Treatment decision-making strategies and influences in patients with localized prostate carcinoma.

Gwede CK, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen PB.

Cancer. 2005 Oct 1;104(7):1381-90.

6.

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy FC; ProtecT study group.

Lancet Oncol. 2014 Sep;15(10):1109-18. doi: 10.1016/S1470-2045(14)70361-4. Epub 2014 Aug 19. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.

7.

Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.

Nieder AM, Porter MP, Soloway MS.

J Urol. 2008 Nov;180(5):2005-9; discussion 2009-10. doi: 10.1016/j.juro.2008.07.038. Epub 2008 Sep 17.

PMID:
18801517
8.

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S, Norlén BJ, Widmark A.

Acta Oncol. 2004;43(4):316-81. Review.

PMID:
15303499
9.

Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.

Ferrer M, Guedea F, Suárez JF, de Paula B, Macías V, Mariño A, Hervás A, Herruzo I, Ortiz MJ, Ponce de León J, Sancho G, Boladeras A, Ayala A, Craven-Bratle J, Ávila M, Cunillera O, Pardo Y, Alonso J, Aguiló F; Clinically Localized Prostate Cancer.

Radiother Oncol. 2013 Aug;108(2):306-13. doi: 10.1016/j.radonc.2013.05.038. Epub 2013 Jul 9.

PMID:
23849168
11.

Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.

van Vugt HA, Roobol MJ, van der Poel HG, van Muilekom EH, Busstra M, Kil P, Oomens EH, Leliveld A, Bangma CH, Korfage I, Steyerberg EW.

BJU Int. 2012 Jul;110(2):180-7. doi: 10.1111/j.1464-410X.2011.10679.x. Epub 2011 Nov 23.

PMID:
22112199
12.

Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.

Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR.

BJU Int. 2011 Apr;107(8):1232-7. doi: 10.1111/j.1464-410X.2010.09589.x.

PMID:
20804478
13.

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S.

BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x. Review.

PMID:
22239226
14.
15.

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.

BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.

PMID:
22540922
16.

Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer.

Peschel RE, Colberg JW.

Lancet Oncol. 2003 Apr;4(4):233-41. Review.

PMID:
12681267
17.

Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.

Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV.

BJU Int. 2012 Jul;110(2):201-5. doi: 10.1111/j.1464-410X.2011.10709.x. Epub 2011 Nov 15.

PMID:
22085233
18.

High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.

Chin YS, Bullard J, Bryant L, Bownes P, Ostler P, Hoskin PJ.

Clin Oncol (R Coll Radiol). 2006 Aug;18(6):474-9.

PMID:
16909971
19.

Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.

Ferrer M, Suárez JF, Guedea F, Fernández P, Macías V, Mariño A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, Craven-Bratle J, Garin O, Aguiló F; Multicentric Spanish Group of Clinically Localized Prostate Cancer.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):421-32. doi: 10.1016/j.ijrobp.2007.12.024. Epub 2008 Mar 5.

PMID:
18325680
20.

SABRE 1 (Surgery Against Brachytherapy - a Randomised Evaluation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low-intermediate risk clinically localised prostate cancer.

Eccles BK, Cross W, Rosario DJ, Doble A, Parker C, Logue J, Little L, Stanton L, Bottomley D.

BJU Int. 2013 Aug;112(3):330-7. doi: 10.1111/bju.12127.

PMID:
23826842
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk